Voice Biomarker Identification for Effects of Deep-Brain Stimulation on Parkinson's Disease
This work addresses the tedious and expensive monitoring of DBS settings for Parkinson's patients, offering a potential biomarker for disease severity, though it is incremental with preliminary evidence from a small sample.
The study investigated the correlation between Parkinson's Disease motor severity and voice features in DBS patients, finding that 6 acoustic features showed significant differences between DBS ON and OFF states, and prosodic features like pause length were negatively correlated with symptom severity.
Deep-Brain Stimulation (DBS) is a therapy used in conjunction with medication to help alleviate the motor symptoms of Parkinson's Disease (PD). However, the monitoring and adjustment of DBS settings is tedious and expensive, requiring long programming appointments every few months. We investigated the possible correlation between PD motor score severity and digitally extracted patient voice features to potentially aid clinicians in their monitoring and treatment of PD with DBS, and eventually enable a closed-loop DBS system. 5 DBS PD patients were enrolled. Voice samples were collected for various voice tasks (single phoneme vocalization, free speech task, sentence reading task, counting backward task, categorical fluency task) for DBS ON and OFF states. Motor scores per the Unified Parkinson's Disease Rating Scale (UPDRS) were also collected for DBS ON and OFF states. Voice samples were then analyzed to extract voice features using publicly available voice feature library sets, and statistically compared for DBS ON and OFF. Of the feature categories explored (Acoustic, Prosodic, Linguistic) 6 features from the GeMAPS feature set for acoustic features demonstrated significant differences with DBS ON and OFF (p<0.05). Prosodic features such as pause length/percentage were found to be negatively correlated with increased motor symptom severity. Non-significant differences were found for linguistic features. These findings provide preliminary evidence for acoustic and prosodic speech features to act as potential biomarkers for PD disease severity in DBS patients. We hope to explore further by expanding our data set, identifying other features, applying machine learning models, and working towards a closed-loop DBS system that can auto-tune itself based on changes in a patient's voice.